Literature DB >> 7693129

Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene.

K Hayasaka1, M Himoro, W Sato, G Takada, K Uyemura, N Shimizu, T D Bird, P M Conneally, P F Chance.   

Abstract

P0, a major structural protein of peripheral myelin, is a homophilic adhesion molecule and maps to chromosome 1q22-q23, in the region of the locus for Charcot-Marie-Tooth neuropathy type 1B (CMT1B). We have investigated P0 as a candidate gene in two pedigrees with CMT1B and found point mutations which are completely linked with the disease (Z = 5.5, theta = 0). The mutations, glutamate substitution for lysine 96 or aspartate 90, are located in the extracellular domain, which plays a significant role in myelin membrane adhesion. Individuals with CMT1B are heterozygous for the normal allele and the mutant allele. Our results indicate that P0 is a gene responsible for CMT1B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693129     DOI: 10.1038/ng0993-31

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  57 in total

1.  Retroviral inhibition of cAMP-dependent protein kinase inhibits myelination but not Schwann cell mitosis stimulated by interaction with neurons.

Authors:  D G Howe; K D McCarthy
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

2.  A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.

Authors:  I V Mersiyanova; A V Perepelov; A V Polyakov; V F Sitnikov; E L Dadali; R B Oparin; A N Petrin; O V Evgrafov
Journal:  Am J Hum Genet       Date:  2000-06-07       Impact factor: 11.025

3.  A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease.

Authors:  Gen Tamiya; Satoshi Makino; Makiko Hayashi; Akiko Abe; Chikahiko Numakura; Masao Ueki; Atsushi Tanaka; Chizuru Ito; Kiyotaka Toshimori; Nobuhiro Ogawa; Tomoya Terashima; Hiroshi Maegawa; Daijiro Yanagisawa; Ikuo Tooyama; Masayoshi Tada; Osamu Onodera; Kiyoshi Hayasaka
Journal:  Am J Hum Genet       Date:  2014-08-21       Impact factor: 11.025

4.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

5.  HNMP-1: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury.

Authors:  L M Bolin; T McNeil; L A Lucian; B DeVaux; K Franz-Bacon; D M Gorman; S Zurawski; R Murray; T K McClanahan
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

6.  Phylogenetically Conserved Sequences Around Myelin P0 Stop Codon are Essential for Translational Readthrough to Produce L-MPZ.

Authors:  Yoshihide Yamaguchi; Hiroko Baba
Journal:  Neurochem Res       Date:  2017-10-28       Impact factor: 3.996

Review 7.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

Review 8.  [Genetics of neuropathies].

Authors:  B Gess; A Schirmacher; P Young
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

9.  Charcot-Marie-Tooth disease: a novel Tyr145Ser mutation in the myelin protein zero (MPZ, P0) gene causes different phenotypes in homozygous and heterozygous carriers within one family.

Authors:  Alejandro Leal; Corinna Berghoff; Martin Berghoff; Gerardo Del Valle; Carlos Contreras; Olga Montoya; Erick Hernández; Ramiro Barrantes; Ursula Schlötzer-Schrehardt; Bernhard Neundörfer; André Reis; Bernd Rautenstrauss; Dieter Heuss
Journal:  Neurogenetics       Date:  2003-07-05       Impact factor: 2.660

10.  High frequency of mutations in codon 98 of the peripheral myelin protein P0 gene in 20 French CMT1 patients.

Authors:  H Rouger; E LeGuern; R Gouider; S Tardieu; N Birouk; M Gugenheim; P Bouche; Y Agid; A Brice
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.